UroGen Pharma Statistics

Total Valuation

UroGen Pharma has a market cap or net worth of $1.17 billion. The enterprise value is $1.18 billion.

Market Cap	1.17B
Enterprise Value	1.18B

Important Dates

The next estimated earnings date is Monday, May 11, 2026, before market open.

Earnings Date	May 11, 2026
Ex-Dividend Date	n/a

Share Statistics

UroGen Pharma has 48.71 million shares outstanding. The number of shares has increased by 12.22% in one year.

Current Share Class	48.71M
Shares Outstanding	48.71M
Shares Change (YoY)	+12.22%
Shares Change (QoQ)	+2.44%
Owned by Insiders (%)	2.07%
Owned by Institutions (%)	78.70%
Float	38.68M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	10.65
Forward PS	4.65
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	10.74
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 4.01

Current Ratio	4.01
Quick Ratio	3.31
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-8.14

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-32.10%
Return on Invested Capital (ROIC)	-110.91%
Return on Capital Employed (ROCE)	-81.06%
Weighted Average Cost of Capital (WACC)	11.88%
Revenue Per Employee	$377,278
Profits Per Employee	-$527,471
Employee Count	291
Asset Turnover	0.45
Inventory Turnover	0.97

Taxes

In the past 12 months, UroGen Pharma has paid $78,000 in taxes.

Income Tax	78,000
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +144.38% in the last 52 weeks. The beta is 1.44, so UroGen Pharma's price volatility has been higher than the market average.

Beta (5Y)	1.44
52-Week Price Change	+144.38%
50-Day Moving Average	20.29
200-Day Moving Average	20.33
Relative Strength Index (RSI)	62.64
Average Volume (20 Days)	795,294

Short Selling Information

The latest short interest is 7.83 million, so 16.07% of the outstanding shares have been sold short.

Short Interest	7.83M
Short Previous Month	8.35M
Short % of Shares Out	16.07%
Short % of Float	20.23%
Short Ratio (days to cover)	10.98

Income Statement

In the last 12 months, UroGen Pharma had revenue of $109.79 million and -$153.49 million in losses. Loss per share was -$3.19.

Revenue	109.79M
Gross Profit	97.34M
Operating Income	-124.86M
Pretax Income	-153.42M
Net Income	-153.49M
EBITDA	-124.56M
EBIT	-124.86M
Loss Per Share	-$3.19

Full Income Statement

Balance Sheet

The company has $120.46 million in cash and $130.09 million in debt, giving a net cash position of -$9.63 million or -$0.20 per share.

Cash & Cash Equivalents	120.46M
Total Debt	130.09M
Net Cash	-9.63M
Net Cash Per Share	-$0.20
Equity (Book Value)	-105.47M
Book Value Per Share	-2.18
Working Capital	139.61M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$162.44 million and capital expenditures -$289,000, giving a free cash flow of -$162.73 million.

Operating Cash Flow	-162.44M
Capital Expenditures	-289,000
Depreciation & Amortization	307,000
Net Borrowing	-1.86M
Free Cash Flow	-162.73M
FCF Per Share	-$3.34

Full Cash Flow Statement

Margins

Gross margin is 88.66%, with operating and profit margins of -113.73% and -139.81%.

Gross Margin	88.66%
Operating Margin	-113.73%
Pretax Margin	-139.74%
Profit Margin	-139.81%
EBITDA Margin	-113.45%
EBIT Margin	-113.73%
FCF Margin	n/a

Dividends & Yields

UroGen Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-12.22%
Shareholder Yield	-12.22%
Earnings Yield	-13.13%
FCF Yield	-13.92%

Analyst Forecast

The average price target for UroGen Pharma is $29.29, which is 21.43% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$29.29
Price Target Difference	21.43%
Analyst Consensus	Strong Buy
Analyst Count	7
Revenue Growth Forecast (5Y)	37.65%
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

UroGen Pharma has an Altman Z-Score of -6.02 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-6.02
Piotroski F-Score	1